Accumulation of p53 protein and retinoic acid receptor β in retinoid chemoprevention

Clinical Cancer Research

Volumn 3, Issue 6, 1997, Pages 875-880

  Shin, Dong M ^a,b   Xu, Xiao Chun ^a   Lippman, Scott M ^a   Lee, J Jack ^a   Lee, Jin S ^a   Batsakis, John G ^a   Ro, Jae Y ^a   Martin, Jack W ^a   Hittelman, Walter N ^a   Lotan, Reuben ^a   Hong, Waun Ki ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ISOTRETINOIN; PROTEIN P53; RETINOIC ACID RECEPTOR BETA; RETINOID; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; BIOPSY; CHEMOPROPHYLAXIS; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; IN SITU HYBRIDIZATION; MAJOR CLINICAL STUDY; MALE; MOUTH CANCER; PRECANCER; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTICARCINOGENIC AGENTS; CHEMOPREVENTION; FEMALE; HUMANS; HYPERPLASIA; IN SITU HYBRIDIZATION; ISOTRETINOIN; LEUKOPLAKIA; MALE; MIDDLE AGED; MOUTH NEOPLASMS; RECEPTORS, RETINOIC ACID; RNA, MESSENGER; TRANSCRIPTION, GENETIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0030988737     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Lippman, S. M., Benner, S. E., and Hong, W. H. K. Cancer chemoprevention. J. Clin. Oncol., 12: 851-873, 1994.
2. Lippman, S. M., and Hong, W. K. Not yet standard: retinoids versus second primary tumor. J. Clin. Oncol., 11: 1204-1207, 1993.
3. Hong, W. K., Endicott, J., Itri, L. M., Doos, W., Batsakis, J. G., Bell, R., Fofonoff, S., Byers, R., Atkinson, E. N., Vaughan, C., Toth, B. B., Kramer, A., Dimery, I. W., Skipper, P., and Strong, S. 13-cis-retinoic acid in the treatment of oral leukoplakia. N. Engl. J. Med., 315: 1501-1505, 1986.
4. Lippman, S. M., Batsakis, J. G., Toth, B. B., Weber, R. S., Lee, J., J., Martin, J. W., Hays, G. J., Goepfert, H., and Hong, W. K. Comparison of low-dose isotretinoin with β-carotene to prevent oral carcinogenesis. N. Engl. J. Med., 328: 15-20, 1993.
5. Hong, W. K., Lippman, S. M., Itri, L. M., Karp, D. D., Lee, J. S., Byers, R. M., Schantz, S. S., Kramer, A. M., Lotan, R., Peters, L. L., Dimery, I. W., Brown, B. W., and Goepfert, H. Prevention of second primary tumors with isotretinoin in squamous cell carcinoma of the head and neck. N. Engl. J. Med., 323: 795-801, 1990.
6. Benner, S. E., Pajak, T. F., Lippman, S. M., Earley, C., and Hong, W. K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck: long-term follow-up. J. Natl. Cancer Inst., 86: 140-141, 1994.
7. Chiesa, F., Tradat, I. N., Marazza, M., Rossi, N., Boracchi, P., Mariani, L., Clerici, M., Formelli, F., Barzan, L., Carrassi, A., Pastorini, A., Camerini, T., Giardini, R., Zurrida, S., Minn, F. L., Costa, A., De Palo, G., and Veronesi, U. Prevention of local relapse and new localizations of oral leukoplakia with the synthetic retinoid ferretinide (4-HPR). Preliminary results. Eur. J. Cancer & Clin. Oncol., 8B: 97-102, 1992.
8. Pastorino, U., Infante, M., Maioli, M., Chiesa, G., Buyse, M., Pirket, P., Rosementz, N., Clerici, M., Soresi, E., Valente, M., Belloni, P. A., and Ravasi, G. Adjuvant treatment of stage I lung cancer with high-dose vitamin A. J. Clin. Oncol., 11: 1216-1222, 1993.
9. Boyle, J. O., Hakim, J., Koch, W., van der Riet, P., Hruban, R. H., Roa, R. A., Correo, R., Eby, Y. J., Ruper, J. M., and Sidransky, D. The incidence of p53 mutations increases with progression of head and neck cancer. Cancer Res., 53: 4477-4480, 1993.
10. Girod, S. C., Krueger, G., and Pape, H. D. p53 and ki67 expression in preneoplastic and neoplastic lesions of the oral mucosa. Int. J. Oral Maxillofac. Surg., 22: 285-288, 1993.
11. Shin, D. M., Kim, J., Ro, J. Y., Hittelman, J., Roth, J. A., Hong, W. K., and Hittelman, W. N. Activation of p53 gene expression in premalignant lesions during head and neck tumorigenesis. Cancer Res., 54: 321-326, 1994.
12. Harris, C. C., and Hollstein, M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med., 329: 1318-1327, 1993.
13. Lowe, S., Bodis, S., McClatchey, A., Remington, L., Ruly, H. E., Fisher, D. E., Housman, D. E., and Jacks, T. p53 status and the efficacy of cancer therapy in vivo. Science (Washington DC), 266: 807-810, 1994.
14. Shin, D. M., Lee, J. S., Lippman, S. M., Lee, J. J., Tu, Z. N., Choi, G., Heyne, K., Shin, H. J. C., Ro, J. Y., Goepfert, H., Hong, W. K., and Hittelman, W. N. p53 expression: predicting recurrence and second primary tumors in head and neck squamous cell carcinoma. J. Natl. Cancer Inst., 88: 519-529, 1996.
15. Lippman, S. M., Shin, D. M., Lee, J. J., Batsakis, J. G., Lotan, R., Tainsky, M. A., Hittelman, W. N., and Hong, W. K. p53 and retinoid chemoprevention of oral carcinogenesis. Cancer Res., 55: 16-19, 1995.
16. Mangelsdorf, D. J., Umesono, K., and Evans, R. M. The retinoid receptors. In: M. B. Sporn, A. B. Roberts, and D. S. Goodman (eds.), The Retinoids, pp. 319-350. New York: Raven Press, 1994.
17. Chambon, P. The retinoid signaling pathway: molecular and genetic analyses. Semin. Cell Biol. 5: 115-125, 1994.
18. Morris-Kay, G. Retinoic acid receptors in normal growth and development. Cancer Surv., 14: 181-193, 1992.
19. Gudas, L. J. Retinoids, retinoid-responsive genes, cell differentiation, and cancer. Cell Growth & Differ., 3: 655-662, 1992.
20. Heyman, R. A., Mangelsdorf, D. J., Dyck, J. A., Stein, R. B., Eichele, G., Evans, R. M., and Thaller, C. 9-cis-retinoic acid is a high affinity ligand for the retinoid X receptor. Cell, 68: 397-406, 1992.
21. Levin, A. A., Sturzenbecker, L. J., Kazmer, S., Bosakowski, T., Huselton, C. Allenby, G., Speck, J., Kratzeisen, C., Rosenberger, M., Lovey, A., and Grippo, J. F. 9-cis-retinoic acid stereoisomer binds and activates the nuclear receptor RXRs. Nature (Lond.), 355: 359-361, 1992.
22. Lotan, R., Xu, X-C., Lippman, S. M., Ro, J. Y., Lee, J. S., Lee, J. J., and Hong, W. K. Suppression of retinoic acid receptor-β in oral premalignant lesions and its up-regulation by isotretinoin. N. Engl. J. Med., 332: 1405-1410, 1995.
23. Shin, H. J. C., Shin, D. M., Shah, T., and Ro, J. Y. Methods in pathology: optimization of proliferating cell nuclear antigen immunohistochemical staining by microwave heating in zinc sulfate solution. Mod. Pathol., 7: 242-248, 1994.
24. Xu, X-C., Ro, J. Y., Lee, J. S., Shin, D. M., Hong, W. K., and Lotan, R. Differential expression of nuclear retinoid receptors in normal, premalignant, and malignant head and neck tissues. Cancer Res., 54: 3580-3587, 1994.
25. Xu, X-C., Clifford, J. L., Hong, W. K., and Lotan, R. Detection of nuclear retinoic acid receptor mRNA in histological tissue sections using nonradioactive in situ hybridization histochemistry. Diagn. Mol. Pathol., 3: 122-131, 1994.
26. Woolson, R. F. Statistical Methods for the Analysis of Biomedical Data. New York: John Wiley & Sons, Inc., 1987.
27. Iggo, R., Gatter, K., Bartek, J., Lane, D., and Harris, A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet. 335: 675-679, 1990.
28. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
29. Kuerbitz, S. J., Plunkett, B. S., Walsh, W. V., and Kastan, M. B. Wild-type p53 of a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
30. Livingstone, L. R., White, A., Sprouse, J., Livanos, E., Jacks, T., and Tisty, T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell, 70: 923-935, 1992.
31. Lowe, S. W., Ruley, H. E., Jacks, T., and Housman, D. E. p53-dependent apoptosis modulates the cytotoxicity of anticancer agents. Cell, 74: 957-967, 1993.
32. Moghal, N., and Neel, B. G. Evidence for impaired retinoic acid receptor-thyroid hormone receptor AF-2 cofactor activity in human lung cancer. Mol. Cell. Biol., 15: 3945-3959, 1995.
33. WAF1 and apoptosis by a RXR-selective retinoid in human prostate cancer cells. Proc. Am. Assoc. Cancer Res., 37: 230, 1996.
34. Greenblatt, M. S., Bennett, W. P., Hollstein, M., and Harris, C. C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res., 54: 4855-4878, 1994.
35. Voravud, N., Shin, D. M., Ro, J. Y., Lee, J. S., Hong, W. K., and Hittelman, W. N. Increased polysomies of chromosomes 7 and 17 during head and neck multistage carcinogenesis. Cancer Res., 53: 2874-2883, 1993.
36. Shin, D. M., Voravud, N., Ro, J. Y., Lee, J. S., Hong, W. K., and Hittelman, W. N. Sequential up-regulation of proliferating cell nuclear antigen in head and neck tumorigenesis: a potential biomarker. J. Natl. Cancer Inst., 85: 971-978, 1993.
37. Papadimitrakapoulou, V., Shin, D. M., and Hong, W. K. Biomarkers in head and neck cancer. Cancer Metastasis Rev., 15: 53-76, 1996.
38. Shin, D. M., Ro, J. Y., Hong, W. K., and Hittelman, W. N. Dysregulation of epidermal growth factor receptor during head and neck tumorigenesis. Cancer Res., 54: 3153-3159, 1994.
39. Mao, L., Lee, J. S., Fan, Y. H., Ro, J. Y., Batsakis, J. G., Lippman, S. M., Hittelman, W. N., and Hong, W. K. Frequent microsatellite alterations at chromosomes 9p21 and 3p14 in oral premalignant lesions and their value in cancer risk assessments. Nat. Med., 2: 682-685, 1996.